Pioneering the field of drug-device convergence for targeted therapies.
TARIS Biomedical is pioneering the field of
drug-device convergence for targeted therapies
TARIS Biomedical Inc. is a specialty pharmaceutical company focused on local
minimally-invasive drug-device convergence products. TARIS core technology and
development efforts are focused on high unmet need disease areas in which
current therapies or systemic treatments have failed. TARIS Biomedical
has several drug-device convergence program opportunities.
Read More
News and Events
Nov 6, 2009
TARIS Appoints Julie Lekstom Himes, MD, to CMO post
READ MORE
June 24, 2009
TARIS Biomedical Launches with $15 Million in Funding
READ MORE
